48 results about "Type i diabetes" patented technology

The invention relates to the field of medicine synthesis, and discloses a GLP-1 / GIP / GCG tri-agonist compound. The GLP-1 / GIP / GCG three-agonist compound is used for preparing a medicine composition for treating diseases, and the application of the medicine composition in preparing a medicine for treating at least one of the following diseases, namely, the GLP-1 / GIP / GCG three-agonist compound, and the GLP-1 / GIP / GCG three-agonist compound. The diseases include type II diabetes mellitus, impaired glucose tolerance, type I diabetes mellitus, obesity, hypertension, metabolic syndrome, dyslipidemia, cognitive impairment, atherosclerosis, myocardial infarction, coronary heart disease, cardiovascular disease, stroke, inflammatory bowel syndrome and / or dyspepsia or gastric ulcer, hepatic fibrosis disease and pulmonary fibrosis disease.

The invention relates to the field of medicine synthesis, and discloses a GLP-1 / GIP / GCG tri-agonist compound. The GLP-1 / GIP / GCG three-agonist compound is used for preparing a medicine composition for treating diseases, and the application of the medicine composition in preparing a medicine for treating at least one of the following diseases, namely, the GLP-1 / GIP / GCG three-agonist compound, and the GLP-1 / GIP / GCG three-agonist compound. The diseases include type II diabetes mellitus, impaired glucose tolerance, type I diabetes mellitus, obesity, hypertension, metabolic syndrome, dyslipidemia, cognitive impairment, atherosclerosis, myocardial infarction, coronary heart disease, cardiovascular disease, stroke, inflammatory bowel syndrome and / or dyspepsia or gastric ulcer, hepatic fibrosis disease and pulmonary fibrosis disease.

A computer-implemented method for treating a patient suffering from Type I Diabetes (T1D). The method can include quantifying physical activity (PA) of the patient; calculating an accumulated PA periodically based on the quantified PA, the accumulated PA indicating an aggregate of the PA; and generating an activity informed insulin bolus by adjusting a prevalent functional insulin therapy bolus with a previous activity component, wherein the previous activity component is based on the accumulated daily PA, an activity profile, and an activity factor of the patient. The method can include determining an additional glucose uptake within a time period, the additional glucose uptake being caused by a PA; translating the additional glucose uptake into a number of insulin units with a same BG lowering impact; and generating an activity informed insulin bolus by adjusting a prevalent functional insulin therapy bolus with the insulin units.

The invention relates to the field of medicine synthesis, and discloses a GLP-1 / GCG dual-agonist compound. The GLP-1 / GCG dual-agonist compound provided by the invention is used for preparing a pharmaceutical composition for treating diseases, and application of the pharmaceutical composition in preparation of a medicine for treating at least one of the following diseases, the diseases include type II diabetes mellitus, impaired glucose tolerance, type I diabetes mellitus, obesity, hypertension, metabolic syndrome, dyslipidemia, cognitive impairment, atherosclerosis, myocardial infarction, coronary heart disease, cardiovascular disease, stroke, inflammatory bowel syndrome and / or dyspepsia or gastric ulcer, hepatic fibrosis disease and pulmonary fibrosis disease.

The invention relates to the technical field of biomedicine, in particular to siRNA (small interfering ribonucleic acid) for interfering Tc11a gene expression, a core-shell type nano particle as well as a preparation method and application of the core-shell type nano particle. The invention relates to a method for treating type I diabetes mellitus by using core-shell nanoparticles (siTc11a NPs) of a targeted mouse Tc11a gene on an NOD model mouse, and provides a preparation method of the nanoparticles. The preparation method comprises the following steps: mixing siRNA (small interfering ribonucleic acid) interfering with a Tc11a gene with cationic liposome G0-C14 to obtain a complex; mixing the complex with a polylactic acid-glycolic acid copolymer to obtain a core substance; and mixing the core substance with the lipid polymer to obtain the core-shell nanoparticles. The invention provides a treatment strategy for treating the type I diabetes mellitus through targeted Tcl1a gene regulation and control.

The invention also relates to an application of the fenerenone or the hydrate, the solvate, the pharmaceutically acceptable salt or the polymorph of the fenerenone for preventing or treating the chronic kidney disease of a diabetes mellitus I patient, which comprises the step of administering a therapeutically effective amount of the fenerenone or the hydrate, the solvate, the pharmaceutically acceptable salt or the polymorph of the fenerenone to the patient.

The present invention relates to a method for improving glucose homeostasis and / or lowering plasma glucose levels by administering a SIRT6 activator. The present invention also provides a method for treating hyperglycemia, prediabetes, and diabetes, including type I diabetes, type II diabetes, or gestational diabetes, by administering a SIRT6 activator.

The invention provides a novel Kv1.3 channel (or Kv1.3) inhibitor which can be used for preventing and / or treating diseases related to the Kv1.3 channel (or Kv1.3), including immune and inflammatory diseases such as multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, type I diabetes, psoriasis and asthma, spondylitis, periodontitis; and obesity, type 2 diabetes, renal fibrosis, Alzheimer's disease, ischemic stroke and the like.

Provided herein are, inter alia, CD6 targeting CAR-T cell compositions and methods useful for treating autoimmune diseases (e.g., Type I diabetes).

The present disclosure is generally directed to the use of biomaterial scaffolds engineered with SA-FasL for the transplantation of stem cell derived β-cells as a treatment for Type I diabetes. Early engraftment post-transplantation and subsequent maturation of these β-cells may be limited by the initial inflammatory response, which impacts the ability to sustain normoglycemia at long times. The survival and development of immature hPSC-derived β-cells transplanted on poly(lactide-co-glycolide) (PLG) microporous scaffolds into the peritoneal fat, a site being considered for clinical translation, was investigated. The scaffolds were modified with biotin for binding of a streptavidin-FasL (SAFasL) chimeric protein to modulate the local inflammatory microenvironment. The presence of FasL impacted infiltration of monocytes and neutrophils and altered their phenotypic response. Conditioned media generated from scaffolds explanted at day 4 did not impact hPSC-derived β-cell survival and maturation in vitro, which was not observed with unmodified scaffolds. Following transplantation, β-cell viability and differentiation were improved with SA-FasL modification. A sustained increase in insulin positive cell ratio was observed with SA-FasL modified relative to unmodified scaffolds. These results demonstrate that SA-FasL-modified scaffolds can mitigate initial inflammatory response and enhance β-cell engraftment and differentiation.

Recent studies indicate that sIL7R is involved in the development of autoimmune diseases. The present invention provides methods and compositions for a novel antibody therapeutic against the soluble isoform of the interleukin 7 receptor (sIL7R), a potent driver of self-destructive immune responses that cause autoimmune diseases including multiple sclerosis, lupus nephritis, type I diabetes, rheumatoid arthritis, systemic lupus erythematosus, and many other autoimmune diseases. The present invention includes antibodies specific for sIL7R that inhibit SIL7R, a driver of autoimmunity, without inhibiting mIL7R, thereby reducing the severity of or preventing autoimmunity without activating immunosuppressive mechanisms.

Provided herein is a synthetic polypeptide derived from a high mobility group cassette 1 (HMGB1) host protein that can both disrupt bacterial biofilm and prevent the formation of neutrophil extracellular traps (NETs). Also provided herein are methods of disrupting abnormal or excessive NET formation, which are particularly suitable for treating high risk populations, the composition can be used for people suffering from infection of SARS CoV-2, septicemia, autoimmune diseases (such as systemic lupus erythematosus, rheumatoid arthritis, type I diabetes mellitus and small vasculitis), autoinflammatory diseases (such as gout and inflammatory bowel disease) and metabolic diseases (such as type 2 diabetes mellitus and obesity).

Provided herein are methods related to delivery of stem cell-derived cell therapies, including stem cell derived islet cell therapies, and related compositions, uses and articles of manufacture. In particular embodiments, the methods relate administering stem cell-derived islet cells. In some embodiments, the subject has a beta cell related disorder, such as diabetes (e.g. Type I diabetes).

To provide an agent for inhibiting the production of CCL20 and / or the migration of Th17 cells. The present invention also provides a composition for treating, preventing, or improving psoriasis, rheumatoid arthritis, type I diabetes, or systemic lupus erythematosus.SOLUTION: An agent for inhibiting CCL20 production and / or migration of Th17 cells, the agent comprising a fermented plant extract, wherein the fermented plant extract comprises yeasts capable of surviving in pH2 and sporulating in a complete medium, and a composition for treating, preventing, or ameliorating systemic lupus erythematosis, the composition comprising a fermented plant extract, wherein the fermented plant extract comprises yeasts capable of surviving in pH2 and sporulating in a complete medium.SELECTED DRAWING: None

Provided is a GLP-1 / GCG dual agonist compound. The GLP-1 / GCG dual agonist compound is used for preparing a pharmaceutical composition for treating diseases. Provided is a use of the pharmaceutical composition in the preparation of a drug for treating at least one disease of type II diabetes, impaired glucose tolerance, type I diabetes, obesity, hypertension, metabolic syndrome, dyslipidemia, cognitive disorders, atherosclerosis, myocardial infarction, coronary heart disease, cardiovascular disease, stroke, inflammatory bowel syndrome and / or dyspepsia or gastric ulcer, hepatic fibrosis, and pulmonary fibrosis.

The disclosure discloses P. acidilactici CCFM6432 for alleviating depression, food fermented thereby and application thereof. The P. acidilactici CCFM6432 of the disclosure can be used to prepare food, health-care products and drugs with the functions of resisting depression, resisting inflammation, resisting inflammatory bowel disease, resisting obesity and resisting type I diabetes. The disclosure further provides fermented food. The fermented food is produced by fermentation using the P. acidilactici CCFM6432, and the fermented food includes solid food, liquid food, and semi-solid food. The P. acidilactici CCFM6432 has very broad application prospects.

Provided herein are methods of administering engineered islet cells, including functionally modified beta cells containing one or more modifications (such as genetic modifications). In some embodiments, the engineered pancreatic islets are low immunogen cells. In some embodiments, the one or more modifications reduce or eliminate the expression of one or more MHC class I and / or MHC class II human leukocyte antigens, while increasing the expression of one or more tolerogenic factors, such as CD47. In some embodiments, the subject has a beta cell related condition, such as diabetes (e.g., type I diabetes).

The invention relates to an indole derivative shown in general formula (I-1) and its use in preparing drugs for preventing and / or treating indications of S1P receptor related disorders. The indole derivative of the invention is replaced by R1, R2, R5, and R6 at different sites respectively, and the obtained modified indole derivative has excellent biological activity and is an ideal S1P receptor regulator with high efficiency. Compounds of general formula (I-1) can be used to treat and / or prevent Crohn's disease, ulcerative colitis, psoriasis, rheumatoid arthritis, multiple sclerosis, atopic dermatitis, eosinophilic esophagitis, alopecia areata, primary cholangitis, pyoderma gangrenosum, graft-versus-host disease, amyotrophic lateral sclerosis, systemic lupus erythematosus, type I diabetes arteriosclerosis, atherosclerosis, scleroderma, autoimmune hepatitis, acne, microbial infection, viral infection, and other autoimmune and inflammatory diseases.

The present invention provides methods and compositions for a novel antibody therapeutic against the soluble isoform of the interleukin 7 receptor (sIL7R), a potent driver of self-destructive immune responses that cause autoimmune diseases including multiple sclerosis, type I diabetes, rheumatoid arthritis, systemic lupus erythematosus as well as other autoimmune diseases. The present invention includes antibodies specific for sIL7R that inhibit sIL7R, a driver of autoimmunity, without inhibiting mIL7R, thereby reducing the severity of or preventing autoimmunity without activating immunosuppressive mechanisms.

The present invention relates to the field of pharmaceutical synthesis. Provided is a GLP-1 / GIP / GCG triple agonist compound. The GLP-1 / GIP / GCG triple agonist compound is used in the preparation of a pharmaceutical composition for treating diseases. Further provided is the use of the pharmaceutical composition in the preparation of a drug for treating at least one of the following diseases. The diseases comprise type II diabetes, impaired glucose tolerance, type I diabetes, obesity, hypertension, metabolic syndrome, dyslipidemia, cognitive impairment, atherosclerosis, myocardial infarction, coronary heart disease, cardiovascular disease, stroke, inflammatory bowel syndrome and / or dyspepsia or gastric ulcer, hepatic fibrosis disease and pulmonary fibrosis disease.

The present invention relates to the field of pharmaceutical synthesis, and provides a long-acting GLP-1 / GLP-2 dual agonist compound for preparing a pharmaceutical composition for treating diseases and use of the pharmaceutical composition in the preparation of a medicament for treating at least one of the following diseases. The diseases include type II diabetes, impaired glucose tolerance, type I diabetes, obesity, hypertension, metabolic syndrome, dyslipidemia, cognitive disorder, atherosclerosis, myocardial infarction, coronary heart disease, cardiovascular diseases, stroke, inflammatory bowel syndrome, irritable bowel syndrome, dyspepsia or gastric ulcer, hepatic fibrosis diseases, pulmonary fibrosis, etc.

Provided herein are anti-OVA-serine proteinase inhibitor (serpin) B13 monoclonal antibodies and antigen-binding antibody fragments that selectively and specifically bind to an epitope of serpin B13, compositions containing these antibodies and antibody fragments, and methods of using these antibodies and antibody fragments. These antibodies and antigen-binding fragments thereof are useful for inhibiting serpin B13 and for treating serpin B13-related diseases, e.g., type I diabetes.

Provided is a GCG-GLP-1 dual agonist compound. The GCG-GLP-1 dual agonist compound is used for preparing a pharmaceutical composition for treating diseases. Further provided is the use of the pharmaceutical composition in the preparation of a drug for treating at least one of the following diseases. The diseases comprise type II diabetes, impaired glucose tolerance, type I diabetes, obesity, hypertension, metabolic syndrome, dyslipidemia, cognitive impairment, atherosclerosis, myocardial infarction, coronary heart disease, cardiovascular disease, strokes, inflammatory bowel syndrome and / or dyspepsia or gastric ulcers, hepatic fibrosis disease and pulmonary fibrosis disease.

The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and / or inflammatory diseases.

The present invention provides a novel Kv1.3 channel (or Kv1.3) inhibitor, which can be used for preventing and / or treating Kv1.3 channel (or Kv1.3)-related diseases, including immune and inflammatory diseases, such as multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, type I diabetes, psoriasis and asthma, spondylitis and periodontitis; and obesity, type 2 diabetes, renal fibrosis, Alzheimer's disease, and ischemic stroke.

The present application relates to the field of medicine synthesis, disclose a long-acting dual agonist compound. The tirzepatide derivative described in the application is used for preparing a pharmaceutical composition for treating diseases, the use of the pharmaceutical composition in the preparation of a medicine for treating at least one of the following diseases, the diseases include type II diabetes, impaired glucose tolerance, type I diabetes, obesity, hypertension, metabolic syndrome, dyslipidemia, cognitive impairment, atherosclerosis, myocardial infarction, coronary heart disease, cardiovascular disease, stroke, inflammatory bowel syndrome and / or indigestion or gastric ulcer, liver fibrosis disease and pulmonary fibrosis disease.

Described herein are FasL-engineered biomaterials, as well as methods of making and using such FasL-engineered biomaterials, such as for immunomodulation, such as for inducing immunosuppression and specific immune tolerance, such as for preventing or reducing the risks of rejection of cellular or tissue grafts and / or the treatment of autoimmune disorders such as Type I diabetes. In specific embodiments, the FasL-engineered biomaterials are biotinylated microgels bound to SA-FasL.

Disclosed are: an agent for suppressing the production of CCL20 and / or the migration of Th17 cells, the agent containing a plant fermentation extract, wherein the plant fermentation extract contains yeast that can survive under conditions having a pH value of 2 and that is capable of forming spores in a complete culture medium; and a composition for treating, preventing or ameliorating psoriasis, rheumatoid arthritis, type I diabetes, or systemic lupus erythematosus, the composition containing a plant fermentation extract, wherein the plant fermentation extract contains yeast that can survive under conditions having a pH value of 2 and that is capable of forming spores in a complete culture medium.

The present invention relates to methods for improving glucose homeostasis and / or reducing glucose plasma levels by administering a SIRT6 activator. The invention also provides methods of treating hyperglycemia, prediabetes mellitus, and diabetes mellitus, including type I diabetes mellitus, type II diabetes mellitus, or gestational diabetes mellitus, by administering a SIRT6 activator.

Provided herein are anti-OVA-serine proteinase inhibitor (serpin) B13 monoclonal antibodies and antigen-binding antibody fragments that selectively and specifically bind to an epitope of serpin B13, compositions containing these antibodies and antibody fragments, and methods of using these antibodies and antibody fragments. These antibodies and antigen-binding fragments thereof are useful for inhibiting serpin B13 and for treating serpin B13-related diseases, e.g., type I diabetes.